Score Breakdown
Below average.
Pulse Biosciences has genuinely differentiated nanosecond PFA technology with impressive early clinical data (96% success at 1 year), but the stock at $1.36B market cap is pricing in a level of commercial success that is years away and far from certain. The company generates essentially zero revenue, burns ~$55-70M annually, has negative gross margins on its only commercial product, and faces well-capitalized incumbents (Boston Scientific, Medtronic, J&J, Abbott) who already have FDA-cleared PFA systems. With $80.7M cash and accelerating burn, significant dilution is inevitable within the projection period. The 20.9% short interest and 18.5 days-to-cover reflect legitimate fundamental skepticism. While the technology may ultimately prove transformative, the current valuation implies a probability-weighted outcome that far exceeds what the clinical and commercial milestones justify at this stage. This is a speculative binary bet being priced as if the favorable outcome is near-certain.
Negative cash flow. Can't value it.
Major red flags in SEC filings.
Slow bleed.
No data.
Tight but ok.
Heavy bearish bets.
Below average.
🐻 Why Bears Hate It
The bear case centers on a massive disconnect between valuation ($1.3B+ market cap) and commercial reality. The company reported just $264,000 in revenue for Q4 2025 against a widening annual net loss of $72.8 million (Source: Simply Wall St). Bears argue the company is a 'cash incinerator' that will require continuous equity dilution to fund its expensive pivotal trials, evidenced by a recent $200 million universal shelf registration and a $60 million ATM agreement with TD Securities (Source: StockInsights.ai).
🔍 What's In The SEC Filings
Pulse Biosciences is a speculative medical technology firm surviving on heavy dilution and the financial support of its Co-Chairman, with governance practices that prioritize executive compensation over performance milestones.
Management rewarded for failed milestones via option modification.
“the Board approved changes to the performance-based vesting conditions of certain unvested outstanding common stock option awards that were improbable of vesting. Specifically, 600,113 performance-based stock option awards were modified to time-based vesting criteria”
Management effectively moved the goalposts by converting performance-contingent equity into guaranteed time-based awards because they were unable to meet the original strategic objectives.
Extreme reliance on a single insider and dilutive rights offerings.
“Robert W. Duggan, the Company’s majority stockholder and Co-Chairman, purchased approximately 88% of the units offered through the 2024 Rights Offering.”
The company issued 6 million units consisting of common stock and warrants; with an 88% take-up by the Chairman, the company is essentially a private vehicle funded by one individual at the expense of potential future dilution (13.3M shares currently excluded as anti-dilutive).
Tight liquidity runway relative to cash burn.
“The Company believes that the existing financial resources are sufficient to continue operating activities at least one year past the issuance date of these consolidated financial statements.”
With a net loss of $72.8M and cash used in operations of $54.1M against a cash balance of $80.7M, the company has roughly 18 months of runway without further equity raises or warrant exercises.
Negative gross margins on initial product launch.
“Product revenue $350... Cost of product revenue $539”
The company is selling its initial Vybrance system at a loss, with costs of goods sold exceeding revenue by 54%, suggesting significant scale or pricing hurdles ahead.
Intrinsic value is heavily compromised by the massive overhang of 13.1M stock options and 405k warrants; the company should be valued as a binary bet on FDA clearance and commercial adoption rather than on current fundamentals.
The 'Small Business' status and lack of ICFR (Internal Control Over Financial Reporting) attestation mean investors have less assurance regarding the accuracy of financial reporting processes.